Vrba et al. [115] clinically evaluated a set of ten DNA methylation biomarkers (LINC01158, CCDC181, PRKCB, TBR1, ZNF781, MARCH11, VWC2, SLC9A3, HOXA7) in NSCLC patients, showing significant differences in the methylation pattern of these biomarkers between NSCLC patients and healthy subjects. This evidence concerns the gene CCDC181 and non-small cell lung carcinoma.